News

Net profit of OneSource Specialty Pharma declined 95.33% to Rs 4.60 crore in the quarter ended March 2026 as against Rs 98.50 crore during the previous quarter ended March 2025. Sales rose 0.53% to Rs 428.22 crore in the quarter ended March 2026 as against Rs 425.95 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 73.80 crore in the year ended March 2026 as against net loss of Rs 17.97 crore during the previous year ended March 2025. Sales declined 1.61% to Rs 1421.59 crore in the year ended March 2026 as against Rs 1444.85 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales428.22425.95 1 1421.591444.85 -2 OPM %21.4742.85 -21.4032.29 - PBDT71.50151.99 -53 197.06317.67 -38 PBT-0.3283.50 PL -82.0343.78 PL NP4.6098.50 -95 -73.80-17.97 -311 Powered by Capital Market - Live News

OneSource Specialty Pharma has allotted 3,150 equity shares under ESOP on 13 May 2026. With this allotment, the paid up equity share capital has increased to 114,645,801 equity shares of Re. 1/- each.

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 13 May 2026.

OneSource Specialty Pharma announced that its partner Orbicular, along with its Canadian front-end partner, has received approval from Health Canada for a generic version of Ozempic� (semaglutide injection). This marks the second generic semaglutide approval in Canada, positioning OneSource partners as the first generic entrants in one of the world`s most significant semaglutide markets. The milestone reflects a closely integrated development and manufacturing model. Orbicular led the product development and technical program for the complex peptide, while OneSource supported the program as the manufacturing partner, providing end-to-end manufacturing capabilities for the Canadian filing. Commercial supply will be supported from OneSource`s US FDA-approved flagship facility in Bengaluru. The approval follows a recent tentative approval in the United States supported by OneSource, further reinforcing the company`s growing presence in complex peptide-based injectable programs and its ability to support global partners across highly regulated markets. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma, said: �We are pleased with these back-to-back approvals from two of our global customers in one of the most important semaglutide markets globally. This milestone reflects the strength of our CDMO platform, our compliance standards, technical expertise, and ability to scale complex drug-device-combination programs for highly regulated markets. Our partnership with Orbicular highlights our role in enabling global commercialization through strong, collaborative ecosystems.�

OneSource Specialty Pharma announced that its partner Dr. Reddy`s Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic�. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support. The partnership is designed to ensure reliable and scalable commercial supply from OneSource`s US-FDA approved flagship manufacturing facility in Bengaluru.Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: �We are pleased to announce that our partner Dr. Reddy`s has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic�. This approval further strengthens our collaboration, combining Dr. Reddy`s expertise in peptide development with OneSource`s CDMO capabilities.�